Indianapolis pharmacy recalls compounded drugs

(AP)—A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.

Nora Apothecary Alternative Therapies of Indianapolis says it is recalling all sterile drugs that have not reached their expiration date. The drugs were made on or before April 19.

The company said it initiated the recall after the found quality control problems that threaten the of its products. If compounded drugs are not sterile they can cause infections, though the company said it has not received any reports of illness.

The FDA is conducting a wave of inspections at compounding pharmacies across the country. The action follows a deadly last year caused by contaminated drugs from a Massachusetts compounding pharmacy.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA cites sanitary issues at specialty pharmacies

Apr 12, 2013

(AP)—The Food and Drug Administration says it has uncovered troubling sterility problems at 30 specialty pharmacies that were inspected following a recent outbreak of meningitis caused by contaminated drugs.

FDA: Georgia pharmacy recalling all sterile drugs

Mar 21, 2013

(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Fla. compounding pharmacy recalls sterile drugs

Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

FDA finds contamination concerns at Ameridose

Nov 12, 2012

(AP)—Federal health inspectors have found more than a dozen sterility problems, including insects, at a drugmaking facility with the same founders as the specialty pharmacy linked to a deadly meningitis outbreak.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments